Drug treatment options for the 2019-new coronavirus (2019-nCoV)

BioScience Trends

Volumn 14, Issue 1, 2020, Pages

  Lu, Hongzhou ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

2019 nCoV; Coronaviruses; Pneumonia

Indexed keywords

ALANINE; ANTIVIRUS AGENT; COVID-19; LOPINAVIR; LOPINAVIR-RITONAVIR DRUG COMBINATION; NUCLEOSIDE; REMDESIVIR; RIBONUCLEOTIDE; RITONAVIR; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SIALIDASE;

BETACORONAVIRUS; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; DRUG COMBINATION; DRUG DEVELOPMENT; HUMAN; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS PNEUMONIA;

ALANINE; ANTIVIRAL AGENTS; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; DRUG COMBINATIONS; DRUG DISCOVERY; HUMANS; LOPINAVIR; NEURAMINIDASE; NUCLEOSIDES; PNEUMONIA, VIRAL; RIBONUCLEOTIDES; RITONAVIR;

EID: 85082096467     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/BST.2020.01020     Document Type: Article

References (18)

1. National Health Commission of the People's Republic of China. Pneumonia epidemic situation of new coronavirus infection on January 23, 2020. http://www.nhc.gov.cn/yjb/s3578/202001/5d19a4f6d3154b9fae328918ed2e3c8a.shtml (accessed January 23, 2020).
2. Natsuko Imai. Report 2: Estimating the potential total number of novel Coronavirus cases in Wuhan City, China. http://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news--wuhan-coronavirus/ (accessed January 23, 2020).
3. Lu H, Stratton CW, Tang YW. Outbreak of Pneumonia of Unknown Etiology in Wuhan China: the Mystery and the Miracle. J Med Virol. 2020. doi: 10.1002/jmv.25678.
4. Kim Y, Liu H, Galasiti Kankanamalage AC, Weerasekara S, Hua DH, Groutas WC, Chang KO, Pedersen NC. Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLoS Pathog. 2016; 12:e1005531.
5. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. J Immunol. 2017; 198:4046-4053.
6. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016; 15:327-47.
7. National Health Commission of the People's Republic of China. Notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 3). http://www.nhc.gov.cn/yzygj/s7653p/202001/f492c9153ea9437bb587ce2ffcbee1fa.shtml (accessed January 23, 2020).
8. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, Kao RY, Poon LL, Wong CL, Guan Y, Peiris JS, Yuen KY; HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.Thorax. 2004; 59:252-256.
9. Arabi YM, Alothman A, Balkhy HH, et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-bβ1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018;19:81.
10. Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, Pan J, Zheng J, Lu B, Guo L, Wang C, Cao B; CAP-China Network. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection. J Infect Dis. 2019; pii: jiz656.
11. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 ; 11:222.
12. Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018; 9: pii: e00221-18.
13. Chow EJ, Doyle JD, Uyeki TM. Influenza virus-related critical illness: prevention, diagnosis, treatment. Crit Care. 2019 ; 23:214.
14. Bleibtreu A, Jaureguiberry S, Houhou N, Boutolleau D, Guillot H, Vallois D, Lucet JC, Robert J, Mourvillier B, Delemazure J, Jaspard M, Lescure FX, Rioux C, Caumes E, Yazdanapanah Y. Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016. BMC Infect Dis. 2018; 18:331.
15. Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019; 5:eaav4580.
16. Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM2, Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016; 90:8924-8933.
17. Ji S, Bai Q, Wu X, Zhang DW, Wang S, Shen JL, Fei GH. Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease. Biomed Pharmacother. 2020;121:109652.
18. Ding Y, Zeng L, Li R, Chen Q, Zhou B, Chen Q, Cheng PL, Yutao W, Zheng J, Yang Z, Zhang F. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function. BMC Complement Altern Med. 2017; 17:130.